Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Drug Profile

Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Alternative Names: ALK Ragweed Tablet; Ambrosia-artemisiifolia-extract-ALK-Abello; MK-3641; Ragweed AIT; Ragweed allergy immunotherapy - ALK-Abello; Ragweed extract - ALK-Abello; Ragwitek; SCH 039641; SCH 39641; SLITone ULTRA

Latest Information Update: 24 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer ALK-Abello; Merck & Co
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 15 Jan 2019 Efficacy and adverse events data from a phase III trial in Seasonal allergic rhinitis released by ALK-Abello
  • 09 Nov 2018 Merck completes a phase III trial in Seasonal allergic rhinitis in USA, North America, Croatia and Hungary (NCT02478398)
  • 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Seasonal-allergic-rhinitis in Hungary (Sublingual, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top